PhytoXtract SA holds an authorisation from Swissmedic, the Swiss Agency for Therapeutic Products, for the manufacture (GMP) and distribution (GDP) of medicinal products. All tasks relating to manufacture and analysis of our products are carried out in accordance with the requirements of GMP (Good Manufacturing Practices). All tasks relating to the distribution are carried out in accordance with the requirements of GDP (Good Distribution Practices).
Accordingly, cannabis based raw materials are extracted, for the production of pharmaceuticals and cannabis based formulations for swiss pharmacies. Export of solutions with THC%<1% depends on country of destination; legal requirements differ widely.
Pharmacies are therefore able to produce themselves with our bulk production, but also out-source the production in small quantities of formulations.